Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GeneGo, a provider of software and databases for systems biology, has announced that KineMed has licensed MetaCore for application to its ongoing multi-center Phase II prognostic study of chronic lymphocytic leukemia.
Subscribe to our email newsletter
KineMed’s kinetic biomarker of chronic lymphocytic leukemia flux as a predictor of disease course is intended to stratify indolent (simmering) versus aggressive disease.
GeneGo’s genetic pathway database aligns with KineMed’s phenotypic pathway analysis and facilitates identification of genetic polymorphisms and expression patterns that directly link genetics with KineMed’s in vivo disease biomarker.
Gregory Hayes, director of oncology research at KineMed, said: “KineMed’s biological pathway insights and GeneGo’s database for systems biology link network complexity to physiologic phenotypes and disease genotypes which is one of the primary goals for personalized medicine.”